Results 1 to 10 of about 37,162 (308)
Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics? [PDF]
Biomedicines, 2022 Schizophrenia (SCZ) is a complex psychiatric disorder of multifactorial origin, in which both genetic and environmental factors have an impact on its onset, course, and outcome.
Olga Płaza +5 more
doaj +2 more sources
Second-generation antipsychotics - a panacea?
South African Journal of Psychiatry, 2004 NO ABSTRACT ...
Paul D Carey, Dan Stein, Robin Emsley
doaj +3 more sources
Second-generation antipsychotics and metabolic syndrome: a role for mitochondria [PDF]
Frontiers in Psychiatry, 2023 Psychosis is a known risk factor for developing metabolic syndrome (MetS). The risk is even greater in patients who are taking second-generation antipsychotics (SGAs).
Katherine R. H. Mortimer +3 more
doaj +2 more sources
Neutropenia induced by several second-generation antipsychotics :A case report [PDF]
European Psychiatry, 2023 Introduction Antipsychotic medications remain the mainstay of the treatment of various psychiatric disorders, particularly schizophrenia. However, this therapeutic class can induce a range of side effects.
H. Zarouf +3 more
doaj +2 more sources
Sex differences in side effects of second-generation antipsychotics [PDF]
Annals of General Psychiatry, 2008 Paterakis Perikles +2 more
doaj +2 more sources
First- and Second-Generation Antipsychotics [PDF]
The Canadian Journal of Psychiatry, 2010 Joseph P McEvoy, MD1; Daniel Zigman, MD2; Howard C Margolese, MD, CM, MSc, FRCPC3 Can J Psychiatry. 2010;55(3):144-149. Are SGAs Better Than FGAs? No The FGAs are a group of drugs with the common pharmacological action of D2 blockade. D2 blockade offers impressive (relative to placebo) but limited therapeutic benefit in the treatment of acute psychotic
Joseph P, McEvoy +2 more
openaire +2 more sources
Archives of Mental Health, 2020 Introduction: The prevalence of metabolic syndrome is more in patients with schizophrenia receiving first- and second-generation antipsychotics. Aim and Objectives: The aim is to study the prevalence of metabolic syndrome in patients with schizophrenia ...
Dinesh Panati +3 more
doaj +1 more source
Combination treatment with second generation antipsychotics other than clozapine
European Psychiatry, 2021 Background Antipsychotic combination treatment without clozapine is common in the treatment of schizophrenia patients worldwide, despite clinical guidelines generally do not recommend such practice.
C. Schmidt-Kraepelin
doaj +1 more source
Second-generation antipsychotics and pregnancy complications [PDF]
European Journal of Clinical Pharmacology, 2019 Abstract Purpose To study if second-generation antipsychotic (S-GA) use during pregnancy is associated with an increased risk of pregnancy and neonatal complications. Methods A population-based birth cohort study using national register data extracted from the “Drugs and Pregnancy” database in Finland, years 1996–2016.
Maria Ellfolk +6 more
openaire +4 more sources
Antipsychotic use in a resource-limited setting: Findings in an Eastern Cape psychiatric hospital
South African Journal of Psychiatry, 2017 Background: Second-generation antipsychotics (SGAs) are commonly prescribed despite the fact that large, naturalistic studies have failed to show superior efficacy and tolerability when compared with first-generation antipsychotics (FGAs). In addition to
Ingrid Eloff +2 more
doaj +1 more source